Hosted on MSN
EyePoint outlines top-line Phase III DURAVYU data for wet AMD expected mid-2026 as cash runway extends into Q4 2027
Top line data for DURAVYU in wet AMD (LUGANO and LUCIA trials) is expected starting mid-2026. Management reiterated, “Our fully enrolled Phase III pivotal program remains on track to deliver top line ...
The Centers for Medicare & Medicaid Services has responded to a challenge to provide savings information on a competitive bidding process it's implementing for durable medical equipment. On Friday, ...
President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...
– Presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT – WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc.
Operating an in-house durable medical equipment (DME) program can increase both patient satisfaction and profitability. Sustainable, successful programs are built on a solid foundation that includes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results